IFNA1 and hepatocellular carcinoma: Although interferon (IFN)-based regimens have demonstrated their beneficial effects on recurrence and mortality in patients with HCV-related HCC who underwent curative treatment [5,6,7], ineligibility and treatment-related adverse events often limit the applicability of IFN-based treatment and cause a large gap between clinical efficacy and community effectiveness [2].